Vusolimogene Oderparepvec

Summary

Vusolimogene Oderparepvec (CHEMBL4650271) is a phase-3 clinical-stage gene; indicated across 3 conditions including melanoma and neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Gene
• Indications: 3 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650271
Name	Vusolimogene Oderparepvec
Type	Gene
Max phase	3

Also known as: Hsv-1 oncolytic viral strain rp1, Oncolytic virus rp1, RP-1, RP1, Vusolimogene oderparepvec, VUSOLIMOGENE ODERPAREPVEC

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
melanoma	3	MONDO:0005105	EFO:0000756
neoplasm	1	MONDO:0005070	EFO:0000616
squamous cell carcinoma	1	MONDO:0005096	EFO:0000707

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE1/PHASE2	3
PHASE2	2
PHASE3	1
EARLY_PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06264180	PHASE3	RECRUITING	VO and Nivolumab vs Physician’s Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
NCT03767348	PHASE2	ACTIVE_NOT_RECRUITING	Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
NCT04050436	PHASE2	ACTIVE_NOT_RECRUITING	Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
NCT04349436	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
NCT05858229	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1.
NCT06067061	PHASE1/PHASE2	TERMINATED	neoBREASTIM: Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer
NCT06216938	EARLY_PHASE1	RECRUITING	RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
NCT06590480	Not specified	NO_LONGER_AVAILABLE	An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).